Evaluation of Chronic Hepatitis C Patients from Different Aspects Before the Use of Direct Acting Antivirals

Yildiz Kaya S., Mete B., Kaya A., Balkan I. I., Saltoglu N., Tabak F.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.23, sa.1, ss.6-9, 2017 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/vhd.52724
  • Dergi Adı: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.6-9
  • İstanbul Üniversitesi Adresli: Evet

Özet

Objective: Chronic hepatitis C (CHC) virus infection is one of the leading causes of chronic liver disease in all over the world. The prevalence of CHC is almost 0.5-1% in Turkey. Until recently, pegylated-interferon (PEG IFN) alpha in combination with ribavirin was the main treatment of CHC. The aim of the study was to evaluate the real life data of CHC patients.